Silvercrest Asset Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-12,585
| Closed | -$79.5K | – | 825 |
|
|
2022
Q4 | $79.5K | Hold |
12,585
| – | – | ﹤0.01% | 770 |
|
|
2022
Q3 | $64K | Hold |
12,585
| – | – | ﹤0.01% | 775 |
|
|
2022
Q2 | $79K | Hold |
12,585
| – | – | ﹤0.01% | 779 |
|
|
2022
Q1 | $45K | Hold |
12,585
| – | – | ﹤0.01% | 836 |
|
|
2021
Q4 | $63K | Sell |
12,585
-250
| -2% | -$1.51K | ﹤0.01% | 815 |
|
|
2021
Q3 | $94K | Hold |
12,835
| – | – | ﹤0.01% | 832 |
|
|
2021
Q2 | $110K | Hold |
12,835
| – | – | ﹤0.01% | 818 |
|
|
2021
Q1 | $139K | Hold |
12,835
| – | – | ﹤0.01% | 819 |
|
|
2020
Q4 | $127K | Sell |
12,835
-1
| -0% | -$7 | ﹤0.01% | 778 |
|
|
2020
Q3 | $69K | Hold |
12,836
| – | – | ﹤0.01% | 739 |
|
|
2020
Q2 | $75K | Hold |
12,836
| – | – | ﹤0.01% | 723 |
|
|
2020
Q1 | $48K | Hold |
12,836
| – | – | ﹤0.01% | 693 |
|
|
2019
Q4 | $81K | Sell |
12,836
-3,000
| -19% | -$38.1K | ﹤0.01% | 739 |
|
|
2019
Q3 | $218K | Hold |
15,836
| – | – | ﹤0.01% | 681 |
|
|
2019
Q2 | $234K | Hold |
15,836
| – | – | ﹤0.01% | 519 |
|
|
2019
Q1 | $664K | Hold |
15,836
| – | – | 0.01% | 408 |
|
|
2018
Q4 | $658K | Hold |
15,836
| – | – | 0.01% | 376 |
|
|
2018
Q3 | $763K | Hold |
15,836
| – | – | 0.01% | 383 |
|
|
2018
Q2 | $751K | Hold |
15,836
| – | – | 0.01% | 381 |
|
|
2018
Q1 | $974K | Hold |
15,836
| – | – | 0.01% | 360 |
|
|
2017
Q4 | $851K | Sell |
15,836
-2,500
| -14% | -$149K | 0.01% | 374 |
|
|
2017
Q3 | $1.24M | Hold |
18,336
| – | – | 0.01% | 347 |
|
|
2017
Q2 | $993K | Buy |
+18,336
| New | +$849K | 0.01% | 351 |
|
|
2017
Q1 | – | Sell |
-24,322
| Closed | -$777K | – | 591 |
|
|
2016
Q4 | $777K | Buy |
+24,322
| New | +$891K | 0.01% | 370 |
|
Silvercrest Asset Management's FSTX Position: Q1 2023 in Review
Silvercrest Asset Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 12,585 shares — an estimated $79.5K sold.
Silvercrest Asset Management first reported a position in FSTX in Q4 2016 and held it in 24 quarters. The position peaked at $1.24M in Q3 2017. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- Silvercrest Asset Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Silvercrest Asset Management sold 12,585 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $79.5K.
- Silvercrest Asset Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2016 and held it in 24 quarters.
- Silvercrest Asset Management's F-star Therapeutics, Inc. Common Stock position peaked at $1.24M in Q3 2017.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Silvercrest Asset Management's 13F filing for Q1 2023, filed 15 May 2023.